Instrument NameViking TheraInstrument Symbol(VKTX-Q)

Instrument ExchangeNASDAQ

Viking Therapeutics just revealed a new plan that could make waves in the weight loss industry.

Viking stock has slipped more than 20% from its peak.

All signs are pointing toward its continued success.

The company's latest presentation supports the idea that its lead program will make billions.

The clinical-stage drugmaker is developing an anti-obesity drug that could go on to produce record-breaking sales.

Are we ready for the Great Obesity Drug Gold Rush of the 2020s?

The S&P 500 Index ($SPX ) (SPY ) today is up +0.01%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up -0.27%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.15%. Stocks today are moderately lower on long liquidation pressures ahead of the US presidential...

Stocks staged a strong rally on Friday following a steep sell-off; a weak jobs report all but guarantees a rate cut which adds to bullish sentiment

Viking Therapeutics is making headway in the weight loss drug market; but even though the payoff is years away, there's still plenty of upside for investors

It might not be too late to get in on the party.

Viking Therapeutics is making notable advancements in obesity treatment with VK2735 and exploring strategic partnerships for its NASH program, positioning itself at the forefront of metabolic and endocrine disorder therapies

Novo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout star.

The company provided clear evidence that it has plenty of resources to continue developing a potential blockbuster drug.

/CNW/ -- USA News Group News Commentary – With more than 100 million Americans struggling with obesity, and obesity rates increasing on every continent, it's...

Regardless of who wins the presidency, investors are better off focusing on top growth stocks.

Viking Therapeutics Inc (VKTX), a clinical-stage biopharmaceutical company, recently reported its financial results for the third quarter ending September 30, 2024. This quarter has been pivotal for the company, highlighting substantial advancements in its clinical pipeline, financials, and strategic focus on metabolic and endocrine disorders. Before we dive in, we...

Viking recently announced the results of an early-stage clinical trial for VK0214.

We could be witnessing the birth of a major player in the biotech industry.

It's hard to go wrong with either company, but one is more appealing.

This company is operating in one of today's hottest markets.

The investment bank analysts who follow these stocks think they can soar even further, with some caveats.

An analyst waxed bullish on the company's leading pipeline program.

The company is in the spotlight for one of its programs, but it's got others that also have promise.

One of them is performing much better than the other this year.

Viking Therapeutics' promising weight loss drug could revolutionize the obesity market and propel the company's stock price to new highs.